Oppenheimer Holdings Comments on Kura Oncology, Inc.’s Q1 2018 Earnings (KURA)
Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Oppenheimer Holdings issued their Q1 2018 earnings per share estimates for shares of Kura Oncology in a note issued to investors on Sunday. Oppenheimer Holdings analyst L. Cann anticipates that the company will earn ($0.55) per share for the quarter. Oppenheimer Holdings currently has a “Buy” rating and a $16.00 price target on the stock. Oppenheimer Holdings also issued estimates for Kura Oncology’s Q2 2018 earnings at ($0.57) EPS, Q3 2018 earnings at ($0.76) EPS and Q4 2018 earnings at ($0.83) EPS.
Several other equities research analysts have also recently commented on KURA. Leerink Swann reissued an “outperform” rating and set a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Zacks Investment Research cut Kura Oncology from a “buy” rating to a “hold” rating and set a $7.25 target price on the stock. in a report on Wednesday, August 23rd. Citigroup Inc. set a $13.00 target price on Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.00.
Kura Oncology (NASDAQ KURA) traded up 7.8254% during midday trading on Tuesday, hitting $15.4999. The company had a trading volume of 276,865 shares. The stock’s market cap is $309.81 million. The company’s 50 day moving average is $13.54 and its 200 day moving average is $9.97. Kura Oncology has a 12-month low of $4.00 and a 12-month high of $15.70.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.03.
Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wisconsin Investment Board bought a new position in shares of Kura Oncology in the second quarter valued at $102,000. Oppenheimer & Co. Inc. increased its holdings in shares of Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after buying an additional 1,600 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Kura Oncology in the second quarter valued at $131,000. Nationwide Fund Advisors bought a new position in shares of Kura Oncology in the first quarter valued at $136,000. Finally, New York State Common Retirement Fund bought a new position in shares of Kura Oncology in the second quarter valued at $142,000. 40.56% of the stock is currently owned by institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.